Showing 1 - 7 results of 7 for search '(((( 50 ((a decrease) OR (mean decrease)) ) OR ( 10 mg decrease ))) OR ( 50 ms decrease ))~', query time: 0.70s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Image_1_Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing’s Syndrome: Results From a Single Center Cohort Study.jpg by Mario Detomas (11304897)

    Published 2022
    “…This tendency persisted at T2 (-37.3% vs -50.1%; median drug dose: 1250 mg vs 6 mg) while at T3 a decrease in UFC from T0 was more pronounced in the metyrapone group (-71.5% vs -51.5%; median dose 1250 mg vs 7 mg). …”
  5. 5

    Table_1_Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing’s Syndrome: Results From a Single Center Cohort Study.docx by Mario Detomas (11304897)

    Published 2022
    “…This tendency persisted at T2 (-37.3% vs -50.1%; median drug dose: 1250 mg vs 6 mg) while at T3 a decrease in UFC from T0 was more pronounced in the metyrapone group (-71.5% vs -51.5%; median dose 1250 mg vs 7 mg). …”
  6. 6
  7. 7